Literature DB >> 26622446

Clinical efficacy of 'Spleen-kidney-care' Yiqi Huayu and Jiangzhuo traditional Chinese medicine for the treatment of patients with diabetic nephropathy.

Hong Liu1, Jin Zheng1, Rong-Heng Li2.   

Abstract

The aim of the present study was to investigate the effect of the traditional Chinese medicine (TCM), 'Spleen-kidney-care' Yiqi Huayu and Jiangzhuo decoction (SKC-YJ), as an adjuvant therapy in diabetic nephropathy (DN) treatment. In total, 72 patients with DN were randomly divided into control (n=54) and experimental (n=18) groups, with the latter administered SKC-YJ treatment. Indicators for determining the condition of the patients included the levels of proteinuria, blood glucose, glycosylated hemoglobin, blood lipids, blood viscosity and C-reactive protein, which were used to analyze the treatment protocols for DN. Following SKC-YJ treatment, the urinary albumin excretion rate, fasting blood glucose, 2 h-postprandial blood glucose, glycosylated hemoglobin, triglyceride, total cholesterol, blood viscosity, fibrinogen and C-reactive protein levels were detected in the two groups, and were all demonstrated to decrease significantly following treatment with SKC-YJ. Furthermore, the results revealed that SKC-YJ treatment exhibited no significant side-effects on the blood, liver and renal functions or gastrointestinal reactions. By contrast, SKC-YJ improved the symptoms of nausea, vomiting and diarrhea in the patients with DN, while showing no allergic reaction during the observation period. Therefore, SKC-YJ treatment was shown to significantly improve the clinical efficacy of DN treatment, illustrating novel roles for TCM in DN treatment.

Entities:  

Keywords:  Yiqi Huayu Jiangzhuo decoction; blood viscosity; diabetic nephropathy; traditional Chinese medicine syndromes; traditional Chinese medicine treatment for diabetic

Year:  2015        PMID: 26622446      PMCID: PMC4533139          DOI: 10.3892/etm.2015.2627

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

1.  Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.

Authors:  Junnosuke Miura; Sho ichi Yamagishi; Yasuko Uchigata; Masayoshi Takeuchi; Hiroshi Yamamoto; Zenji Makita; Yasuhiko Iwamoto
Journal:  J Diabetes Complications       Date:  2003 Jan-Feb       Impact factor: 2.852

2.  Drug-target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitus.

Authors:  Jiangyong Gu; Hu Zhang; Lirong Chen; Shun Xu; Gu Yuan; Xiaojie Xu
Journal:  Comput Biol Chem       Date:  2011-07-20       Impact factor: 2.877

Review 3.  Clinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy--a systematic review based on a subgroup analysis.

Authors:  Xiaoyu Liu; Ling Liu; Pinyi Chen; Liang Zhou; Yanqi Zhang; Yazhou Wu; Lei Jiang; Dixiang Cheng; Wenquan Huang; Dong Yi
Journal:  J Ethnopharmacol       Date:  2013-12-01       Impact factor: 4.360

Review 4.  Secretion of glycated insulin from pancreatic beta-cells in diabetes represents a novel aspect of beta-cell dysfunction and glucose toxicity.

Authors:  A M McKillop; Y H A Abdel-Wahab; M H Mooney; F P M O'Harte; P R Flatt
Journal:  Diabetes Metab       Date:  2002-12       Impact factor: 6.041

5.  The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke.

Authors:  R Rosmond; P Björntorp
Journal:  J Intern Med       Date:  2000-02       Impact factor: 8.989

6.  Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.

Authors:  D Koya; M Haneda; H Nakagawa; K Isshiki; H Sato; S Maeda; T Sugimoto; H Yasuda; A Kashiwagi; D K Ways; G L King; R Kikkawa
Journal:  FASEB J       Date:  2000-03       Impact factor: 5.191

Review 7.  Advanced glycation endproducts--role in pathology of diabetic complications.

Authors:  Nessar Ahmed
Journal:  Diabetes Res Clin Pract       Date:  2005-01       Impact factor: 5.602

8.  Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial.

Authors:  Vladimir Vuksan; Dana Whitham; John L Sievenpiper; Alexandra L Jenkins; Alexander L Rogovik; Richard P Bazinet; Edward Vidgen; Amir Hanna
Journal:  Diabetes Care       Date:  2007-08-08       Impact factor: 19.112

9.  Current situation and perspectives of clinical study in integrative medicine in china.

Authors:  Jie Wang; Xingjiang Xiong
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-21       Impact factor: 2.629

10.  Efficacy and safety of traditional chinese medicine for diabetes: a double-blind, randomised, controlled trial.

Authors:  Linong Ji; Xiaolin Tong; Hongyuan Wang; Haoming Tian; Huimin Zhou; Lili Zhang; Qifu Li; Yizhong Wang; Hongmei Li; Min Liu; Hongjie Yang; Yanbin Gao; Yan Li; Quanmin Li; Xiaohui Guo; Gangyi Yang; Zhongai Zhang; Zhiguang Zhou; Guang Ning; Yingli Chen; Sanjoy Paul
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more
  1 in total

1.  The Effect of Chinese Medicinal Formulas on Biomarkers of Oxidative Stress in STZ-Induced Diabetic Kidney Disease Rats: A Meta-Analysis and Systematic Review.

Authors:  Qian Zhou; Chuyi Han; Yanmei Wang; Shunlian Fu; Yiding Chen; Qiu Chen
Journal:  Front Med (Lausanne)       Date:  2022-04-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.